Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mongoose- about 6 years ago I was introduced to "DONA" Crystalline Glucosamine Sulfate. It is patented by ROTTAPHARM and is a prescription drug in Europe.
It has been available over the counter in US and Canada for 10 or so year.
I did research on it and there had been two separate blinded controlled studies done on it, both of which I read. One amazing take away from both of the studies was that at the end of the two (as I recall) year studies, those taking DONA had an increase in the distance between the femur and tibia indicating an increase the cartilage while the control group had a decrease. This has been attributed to the patented ingredient as I understand.
I believe you can get the links to the studies from WynnPharm the master distributor for North America. Google
On a related note I also remember reading ratings of Glucosamine products by either Comsumer's Report or Consumer Research that showed the various amount of Glcosamine in various brands, one brand had ZERO Glucosamine in it.
About a year ago the price virtually doubled (shades of Shkreli) so I tried another brand for about six months and noticed a difference. Subsequently the price has come back down some and I have gotten back on the DONA and have noticed quite an improvement.
Question for anyone- When the CEO states H2 is he referring to the fiscal year or calendar year? I haven't had the time to check this out thoroughly myself but I know that all of the brilliant people on this msg. board would have the answer. TIA
I agree with your statements whole heatedly. I live in a retirement community and see too many folks that progress from independent living to assisted living to memory care and then attend their funeral.
It appears from all of the information provided by Anavex and the much appreciated analysis of those members on this message board whom are biologically and/or scientifically proficient, that A2-73 would either stop or possibly reverse progression for some or most of these without any serious side effects.
It would be nice to see FDA and Anavex move as quickly as possible to get this to trial to make it available for the people experiencing this dreaded dementia. It is disgusting to think that there are individuals or groups that are throwing up roadblocks or possibly slowing progress to delay this as much as possible for self enrichment much as is being done in our federal government.
Also, let us pray that the RETT trial starts immediately in hopes of proving positive results to give those dear little ones a shot at life.
It appears that ANAVEX have developed molecules that might rid the world of some vary nasty diseases.
Makemydaze-Thank you for posting this about Goldman Sachs. It certainly points out the reason that Missling is not allowing these type firms to get a foothold in Anavex. Xena and others have stated this numerous times on this board. Let us pray that Dr. Missling with his background experience and understanding of cabal control will succeed in proving and bringing Anavex's pipeline to fruition. May he and Dr. Gottlieb surpass the "Deep State" that exists in the current system.
Last week there were four "Strong Buy" recommendations by analysts. The most recent one from Fidelity. What do they know that we don't know ?????
Maybe Zuckerburg intercepted them!
GrassyKnoll I agree with your well written posits regarding the possible resistance within the FDA. President Trump and Drs. Gottlieb and Missling must have a tremendous battle to fight against the entrenched "old school" employees as well as the political pressures from big pharma.
I always appreciate your posts and am awed by your knowledge considering your disability and how you have overcome it. I would be interested in knowing your educational background and if you obtained it as a blind student. The reason I ask this is that I am impressed with what Gallaudet University has accomplished for the blind and curious if you might have been a student there.
There was a "boxer" for the Safeway store locally in the summer time that was a Gallaudet student. She was one of the most upbeat, pleasant, capable individuals I have known and had her life goals clearly planned out.
Leo, FYI,ihub generously allows all posters to "Private Message" during Happy Hour from 4-5 PM EDT every Friday.
Since this is Friday and Good Friday at that, this is your opportunity to reply to a PM.
Fireman- I agree it would be nice to have more open communication from the company. My feeling; however, is that after the large misleading attack by AF on a very positive PR in November 2015 that led to numerous lawsuits having to be defended causing a great amount of time and money to be expended has resulted in this "lack of communication" since. Missling has been credited for being a wise steward for advancing AVXL with very little money so why give others fodder for more fraudulent lawsuits.
If you aren't familiar with that manipulation of the SP build up and subsequent slam down I recommend reading the message board starting around msg. #22000 or mid Oct. 2015. This is when Jim Craemer's crew of Adam Fuerstein, Martin Shrekli (who is currently serving time) and others attacked Anavex.
I think Dr. Missling is correct in preventing this type of attack from occurring again.
MHPAEA "It is important for panelists such as Dr. Missling to attend in order to lend his expertise in developing therapies for diseases such as Alzheimer's disease as well as other neurological disorders with high unmet needs."
To refresh our memories, Dr. Missling has been invited to the annual MHPAEA Business Roundtable meeting twice. I haven't seen a representative from any big pharma or other bio-tech firm listed to attend either of these business round tables
Fireman - I'm sorry to read about your injury causing you to be removed from the front lines. I experienced the same type rupture 30 years ago and like you only felt the snap and very little pain. I didn't know what had occurred and later noticed that my bicep had rolled up in a ball. I looked like Popeye for a month or so until it was repaired (and like Popeye I love my spinach ).
I live in Oregon and want to express my appreciation for the dangerous work you and your teams do and did in the beautiful Columbia Gorge last year in minimizing the devastation there.
I always look forward to reading your thorough analyses that you share with us here. One (selfish) positive result of your injury is that now you will have more time while recovering to post more often.
Maybe to "stay in your game" while you mend you could get a drone and obtain an exception to flight restrictions over the fire areas and be in the battle vicariously.
Prayers for a speedy and successful recovery.
Jimmy the Annual AAT Conference is June 7 & 8 in London. I might think that this would be where the genome and bio markers would be announced.
I think that Dr. Missling would be the one to present this along with Dr. Hempel since this is the main AD/PD Conference.
BIOchecker - What do you think the Board of Directors position is on this approach. When I look at their backgrounds, it is hard for me to believe they would agree to allow diversionary tactics since it would be their reputations at stake also.
There has been much complaining about Dr. Missling's effectiveness and are calling for his replacement. Anavex is controlled by an outstanding Board of Directors that has complete knowledge of the entire operation and has a fiduciary responsibility to shareholders. In reviewing 10k filings for the past three years, there have been no resignations from the board so they must be satisfied with the direction of the company.
For those that might not be knowledgeable of the make up of the BOD for Anavex, I have copied this from Anavex's December 2017 10-k filing.
Thank you for clarifying this for me. Not knowing exactly what is required on the IND submittal, I assumed that there may have been something stated on it that wouldn't comply with the forthcoming guidance.
I certainly appreciate all of you folks that are thoroughly familiar with FDA requirements and the science of biotechnology that post on this board.
I wont list names for fear that I would miss some of you. I rely on your expertise since my old brain has trouble grasping it all.
FDA has not released the five guidances CNS as they indicated they would do by the end of 2017.
Do you think this might be the reason for the delay??
(Credit Fireman for his post #137842 for this information)
Here is a link to the Erv Heaven video.
Effect of shutdown on FDA continuing to operate.
Budget Director Mick Mulvaney indicates that there will be a minimum of interruption to government operation as he stated on Fox News Sunday today.
The administration will be making use of "carry over funds" for the use that they are intended to maintain operations as much as possible.
You might have missed reading this post regarding RETT trial.
Fireman02360 Wednesday, 01/17/18 12:09:23 PM
Re: loosecargo post# 137836
Post #
137842
of 138225 Go
Retts Trial Update:
This was posted on the Anavex FB page in regards to a email send to the Retts Foundation.
Hello ******, Thank you for your interest in the Anavex Life Sciences Rett syndrome clinical trial study. Anavex has submitted the individual new drug (IND) application . In connection with interactions with the FDA, Anavex is making some adjustments in its planned clinical trial. Anavex will provide updates when the information is available in compliance with the forward looking information rules under the Securities Litigation Reform Act. Feel free to contact Anavex Life Sciences for any questions at www.anavex.com. Thanks
Archive "stickies". I think about archiving these when I see them replaced but as a good procrastinator I don't get it done.
This could be a good service that Investors Hub could provide.
I'll suggest it to admin (when I get around to it. )
Hey Bio- First I really appreciate your well reasoned,very informative and well composed postings.
Now quietly in private I'll point out the spelling of Dr. Fadiran.
I wouldn't want you to loose the respect of 'Kid22' and his friends. LOL.
Now do me favor and tell me how it is pronounced. (Just for curiosity) I posed that question on the board when he was appointed but I didn't agree with what some had suggested.
The sale of 70,000 shares of stock by the CFO has been shown to be a lie.
I presume that it has been restated by you to keep the FUD going at the end of the day.
Here is a portion of Polarbear's post #136148 and a reponse by Basparks.
Thank you for your patient explanations. I appreciate your sharing of knowledge on this board along with the many others that provide us with much good information.
I think I understand but I'm still a little hazy on this.
Is it a matter that the short has to wait until shares are in fact delivered to his/her account before they can actually cover.
Jimmy I was under the impression that for tax purposes that it is the trade date that matters and not the settlement date. I'll have to research that I guess.
BTW I am a solid long term holder so I am not affected one way or other.
There are five companies listed at that address.
61 MOULTON ST. CAMBRIDGE, MA 02138
There are 5 companies that have an address matching 61 Moulton St. Cambridge, MA 02138.
The companies are Biotechnica Diagnostics Inc, Virus Research Institute Inc, Curis Inc, Biotechnica Diagnostics Inc, and Reprogenesis Inc.
BIOTECHNICA DIAGNOSTICS, INC.
MASSACHUSETTS FOREIGN CORPORATION
WRITE REVIEW
Address: 61 Moulton St.
Cambridge, MA 02138
Address Types: Principal
Registered Agent:
Filing Date: June 09, 1989
File Number: 043039970
VIRUS RESEARCH INSTITUTE, INC.
MASSACHUSETTS FOREIGN CORPORATION
WRITE REVIEW
Address: 61 Moulton St.
Cambridge, MA 02138
Address Types: Officer
Registered Agent: Goodwin, Procter & Hoar
Filing Date: December 04, 1991
File Number: 223098869
CURIS INC
TEXAS CORPORATION
WRITE REVIEW
Address: 61 Moulton St.
Cambridge, MA 02138
Address Types: Principal
Registered Agent: Not On File
Filing Date:
File Number: 10435051163
BIOTECHNICA DIAGNOSTICS, INC.
NEW YORK FOREIGN BUSINESS CORPORATION
WRITE REVIEW
Address: 61 Moulton St.
Cambridge, MA 02138
Address Types: Mailing
Registered Agent: The Prentice-Hall
Filing Date: June 15, 1987
File Number: 1179021
REPROGENESIS INC
TEXAS CORPORATION
WRITE REVIEW
Address: 61 Moulton St.
Cambridge, MA 02138
Address Types: Principal
Registered Agent: C T Corporation System
Filing Date: May 29, 1996
File Number: 0140160400
Fireman you made this statement..." Some here speculate the FDA did not think Anavex has enough resources to run 2 trials concurrent to each
other."
I can only recall one poster that might have inferred this. He/she writes as if he/she knows exactly what Missling and or the FDA is thinking and doing as if it is factual rather than indicating that it is "IMO" (Opinion) or conjecture. It can then become "fake news" and misleading if we are not careful.
I might have missed others that have speculated the same and would appreciate knowing if there are more than that one. I place very little credence on these types of ramblings unless they are referenced or a link shown.
I appreciate the many posters on this message board, yours included, with so much experience and knowledge that are so well researched and referenced.
Thank you for your input here.
Jon -An excerpt from NIH news release posted by Penny Double
The ACTC experts and infrastructure will support the design and conduct of trials across the full spectrum of Alzheimer’s and related dementias, from prevention initiatives to combination trials for advanced symptomatic stages. Specific objectives of the consortium include:
Creating infrastructure with expert leadership to streamline implementation of trials
Developing innovative trial design methods, outcomes and analysis strategies
Maintaining trial site quality standards during and between trials
Developing and implementing cutting-edge participant recruitment and retention strategies, especially in diverse populations
Using a centralized Institutional Review Board
Developing and running capture systems for data pertinent to the ACTC
Securing centralized tissue banking for specimens
Providing centralized imaging, biostatistics, bioinformatics and data management and analysis support
Facilitating and managing public-private partnerships
Trials would be conducted harnessing guidance from ACTC leaders, an executive committee and an external advisory board, which will include a patient advocate. The Principal Investigators for the project are:
Paul Stephen Aisen, M.D. (link is external), director of the ATRI at the Keck School of Medicine of USC, San Diego
Reisa A. Sperling, M.D. (link is external), director of the Center for Alzheimer Research and Treatment at the Brigham and Women’s Hospital, professor of Neurology, Harvard Medical School, Boston
Ronald C. Petersen, M.D., Ph.D. (link is external), director of the Mayo Clinic Alzheimer’s Disease Research Center, professor of Neurology at Mayo Clinic College of Medicine and Science, Rochester, Minnesota
The ACTC consists of a coordinating center at ATRI and 10 units staffed with teams to manage areas such as biomarkers, biostatistics, clinical operations, informatics, magnetic resonance imaging, positron emission tomography, and recruitment. As part of its recruitment unit, the ACTC is establishing a new Minority Outreach and Recruitment Team, which will use innovations in recruitment to support both central and local partnerships with diverse communities.
Penny Double Tuesday, 12/12/17 07:14:50 AM
Re: None
Post #
133911
of 134323 Go
https://www.nih.gov/news-events/news-releases/new-nih-consortium-award-enhance-clinical-trials-alzheimers-disease-related-dementias
x
“To me, seeing real improvements to patients is much more important than seeing a statistically significant improvement on a rating scale.
Dr. Macfarlane PI Caufield Hospital Melbourne, Australia
https://www.google.com/search?q=herald+sun+amazing+results+alzheimers&ie=utf-8&oe=utf-8
LinkedIn
Sign in Join now
Main content starts below.
Alzheimer’s disease breakthrough: Melbourne drug trial achieves amazing results (Australia)
Published on December 14, 2016
LikeAlzheimer’s disease breakthrough: Melbourne drug trial achieves amazing results (Australia)6Comment0ShareShare Alzheimer’s disease breakthrough: Melbourne drug trial achieves amazing results (Australia)0
Laurie Hawkins (2,500+)
Laurie Hawkins (2,500+)
FollowLaurie Hawkins (2,500+)
Advocate for Health/Human Services Directories
PATIENTS have woken up from some of the most devastating impacts of Alzheimer’s disease, regaining the ability to play sport, paint and enjoy time with family, after a world-first drug trial in Melbourne.
The remarkable results have fuelled hopes among doctors of the first major improvement in treating the horror disease since the 1990s.
Pianist Pauline Stevens has regained the ability to play the piano after being placed on the experimental Anavex 2-73 drug trial at Caulfield Hospital.
Award-winning artist Valerie Lynch has also rediscovered the ability to paint after beginning the medication, stunning her doctors, family and friends.
When Melbourne was selected as the first city in the world to test Anavex a year ago, lead researcher Associate Professor Steve Macfarlane had no idea how much of an impact it would make.
“They seem to be significantly improved in terms of what they can do. It is function that has improved and in many cases mood as well,” Prof Macfarlane said.
“To me, seeing real improvements to patients is much more important than seeing a statistically significant improvement on a rating scale.
“Seeing people regaining abilities is far more powerful and important than that.”
While the turnaround in the abilities and mood of the 32 patients involved has been the most overwhelming factor, the early data has been equally impressive. It shows a huge improvement in the cognitive ability of the patients, with the drug so far proving to be four-times more effective than the current treatment.
The drug is designed to target the sigma-1 receptor cells that remove abnormal proteins from cells, but which can stop functioning effectively as people age.
By rebooting the process, the drug is hoped to clear the build-up of troublesome proteins believed responsible for neurodegenerative conditions.
Protocols for a much larger controlled trial to begin early next year are now being drawn up as the full results of the trial led by the Caulfield Hospital, but also involving patients from the Austin, Royal Melbourne and St Vincent’s hospitals, are finalised.
After 55 years of playing the piano, Ms Stevens lost the ability to play three years ago, and was soon after diagnosed with Alzheimer’s disease.
Pauline Stevens, 78, has regained the ability to play the piano after taking a revolutionary new drug for Alzheimer's. Picture: David Caird.
Eight months ago she began having a daily pill of Anavex and it is now impossible to wipe the smile from her face as she jokes and plays the piano for her family. “I feel as though I can go and do things now that I couldn’t do. I am happy,” Ms Stevens, 78, said.
“I love playing, I love to sit down and play like I used to.”
Wiping away tears of joy as he listens, husband Tom Stevens said the turnaround has been remarkable.
“Pauline laughs at my jokes again. I have her back,” he said.
“We are at the beginning, but there is hope now where there wasn’t.”
Ms Lynch, 76, has not only picked up her paintbrushes again, but is preparing for an exhibition spanning the last 50 years of her work despite being diagnosed with Alzheimer’s in November 2014.
“People used to say that I had forgotten things or that I had already told them something, and I just said I had a lot to remember and couldn’t remember everything,” Ms Lynch said.
“Everything is better around me. I feel quite well.”
Ms Lynch’s carer Keith Everitt can recall her “going downhill fast” as she stopped painting and had difficulty around her home before joining the trial.
“It has improved her out of all sight. She is laughing and bubbly, she has absolutely blossomed since she has been on these tablets,” he said. “Nobody can believe the difference in Valerie before the trials and now. It is a different person.”
For further information on the Anavex trial, contact adclinicaltrials@cgmc.org.au or visit alfredhealth.org.au.
Those of you complaining about lack of management. Please post your resume. Maybe we could replace one or more of the current Board of Directors with you at the next annual meeting.
Maybe its time to review our BOD which has not had any resignations since being established as I recall. Here is the list:
Management & Directors
Christopher U. Missling, MS, PhD, MBA
Dr. Missling, President and CEO of Anavex®, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex®, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. His career experience also includes working as an investment banker in the healthcare practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, as well as serving as the head of healthcare investment banking at Brimberg & Co. in New York. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management.
Tasos Zografidis, MS, PhD
Dr. Zografidis, the Vice President Clinical Operations of Anavex®, has over 25 years of experience in the pharmaceutical and healthcare industry, including 12 years at Wyeth (now Pfizer) in clinical project management and prior to joining Anavex® most recently served as clinical and pharmaceutical consultant. He has been involved in more than a dozen clinical trials and has co-authored numerous publications. At Wyeth, Dr. Zografidis spearheaded population pharmacokinetics analysis and its implementation in the clinical setting and positively differentiated compounds. His work resulted in increased sales and he received several clinical awards for his accomplishments. Dr. Zografidis first joined Wyeth in 1998 as a Product Manager. During his tenure until 2010, he had increased responsibility as Medical Liaison for the transplantation, haemophilia and oncology divisions where he was instrumental in driving sales in assigned European territories.
Ulrich Elben, PhD
As Vice President of Preclinical Operations for Anavex®, Dr. Elben oversees pipeline development and optimization. Dr. Elben has extensive experience in global pharmaceutical development and research. His background includes roles as VP of Strategic Development Operations at Vertex Pharmaceuticals, with responsibilities including project and portfolio management as well as the development of an oncology project. In addition, Dr. Elben served as a member of the Vertex drug development advisory board and drug product review committee. He was also Chief Development Officer at Avaant Pharmaceuticals, where he led the development of oncology projects across the USA, Europe and India. Earlier in his career, Dr. Elben was CEO of Axxima Pharmaceuticals in Munich, Germany. Dr. Elben started his career with Sanofi-Aventis (former Hoechst Marion Roussel) in Europe and the USA, where his last position was deputy head of project management overseeing also Alzheimer’s and schizophrenia products. He and his teams were successful at bringing several drugs through the international development cycle and ultimately to market. Dr. Elben was also secretary of the Sanofi-Aventis drug development review committee. Additionally, Dr. Elben has extensive, recent consulting experience with VCs, biotech companies and API manufacturing companies in the USA, Canada and Europe. He is currently a member of several organizations, including the CEO advisory board of the Florida Institute for the Commercialization of Public Research, BioFlorida and the Drug Information Association. Dr. Elben received his PhD in organic chemistry from the University of Bonn, Germany.
Emmanuel O Fadiran, RPh, PhD
Dr. Emmanuel O (“Tayo”) Fadiran, the Senior Vice President of Regulatory Affairs has over 26 years of experience in government service, of which 24 years were dedicated to the Food and Drug Administration (FDA). Prior to Anavex®, Dr. Fadiran served as Clinical Pharmacology Team Leader at the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER). During his 24 years (1993-2017) tenure at the FDA he reviewed hundreds of NDAs, sNDAs, BLAs, ANDAs and INDs for approval and strategic recommendations for the development of several products across many therapeutic categories. He was also on review teams for several novel therapies including first in class approvals. Dr. Fadiran also led a cross-disciplinary NDA review team and authored the first Cross-Discipline Team Leader (CDTL) review for the Division of the Pulmonary & Allergy Products, Office of Drug Evaluation II, CDER. He was actively involved in the writing, internal/external training and the implementation of the US FDA Guidance for Industry for population pharmacokinetics.
Dr. Fadiran has been involved in the formulation of significant strategic FDA regulatory initiatives including serving as a member of the Senior Management Teams for the Data Standard (Janus) and Sentinel Initiatives. He was an active member of the FDA Senior Science Council working group for the creation and launching of the FDA’s Strategic Plan for Regulatory Science in 2012. Recently he has played an active role in the development of the Comprehensive in vitro Proarrhythmia Assay (CiPA) for future replacement of the thorough QT studies. As a long-term member of the FDA Institutional Review Board (IRB) he actively contributed to the development of standard operating procedures (SOP) for the committee.
Dr. Fadiran holds a BS (Pharmacy) and MS from Obafemi Awolowo University, Ile-Ife, Nigeria and a PhD in Pharmaceutical Sciences from the University of Strathclyde, Glasgow, UK. Dr. Fadiran is a recipient of the prestigious Fogarty International Fellowship of the National Institutes of Health (NIH) (1991-1993) as well as numerous awards from the FDA, among them the Commissioner’s Award of Excellence, in recognition of his outstanding contributions to regulatory review of applications and development of regulatory guidance and policies.
Bernd Metzner, PhD
Bernd Metzner, PhD, a director of Anavex®, is currently Chief Financial Officer of the Stroeer Group. Previously, he was Chief Administration Officer and member of the Board of Management of Bayer Schering Pharma AG, the pharmaceutical division of $100+ billion market cap company Bayer AG. In this position, Dr. Metzner had worldwide financial responsibility for the Bayer Pharma Group. During his almost 10-years with Bayer AG, Dr. Metzner also held several senior international management positions in the corporate finance organization of Bayer AG, including Chief Financial Officer of Bayer S.p.A. Italy and heading the coordination of the successful spin-off of Lanxess, a specialty chemicals group. Dr. Metzner started his career at the law firm Flick Gocke Schaumburg and has a degree in business administration from the University of Siegen. After obtaining his doctorate, he became a chartered accountant.
Elliot Favus, MD
Elliot Favus, MD, a director of Anavex®, is Chief Executive Officer of Favus Institutional Research, a healthcare research firm serving institutional investors. He has been a healthcare equity research analyst on Wall Street since 2006, starting at Lazard Capital Markets and subsequently at Och-Ziff Capital Management Group. Prior to working on Wall Street, Dr. Favus was an Instructor in medicine at Mount Sinai School of Medicine in New York. He attended the University of Michigan (BA, 1996), the University of Chicago Pritzker School of Medicine (MD, 2001) and the NYU-Bellevue Hospital Internal Medicine Residency Program (2004). He is board-certified in Internal Medicine (2004) and has 10 years of basic science laboratory experience working on human genetics projects at Harvard Medical School, the University of Chicago and the University of Pittsburgh.
Tom Skarpelos
Mr. Skarpelos, a director of Anavex®, is a self-employed investor with 17 years of experience working with private and public companies. For the past 10 years, he has been focused on biotechnology companies involved in drug discovery and drug development projects. Mr. Skarpelos was engaged as a consultant to Anavex®Life Sciences for one year effective August 2, 2010. His experience has led to relationships with researchers at academic institutes in Europe and North America. Mr. Skarpelos is a founder of Anavex®Life Sciences, and is its largest shareholder.
Steffen Thomas, PhD
Steffen Thomas, PhD, a director of Anavex®, has over 15 years of experience as a European patent attorney and is currently practicing at Epping Hermann Fischer, a major intellectual property law firm in Europe. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately USD $10 billion. Dr. Thomas’ legal practice covers drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich.
Peter Donhauser, D.O.
Peter Donhauser, D.O., a director of Anavex®, has more than 20 years of expertise in clinical research followed by practicing osteopathic medicine with an integrated medical approach in private practice since 2000. He worked at the University Hospital of Munich in the fields of geriatrics and neuromusculoskeletal diseases. During this time, he was a clinical trial investigator in multiple Phase 3 studies, including studies sponsored by Merck Sharp & Dohme/Merck, Boehringer Mannheim/Roche, Servier and Sanofi. He received his human medicine degree at the University of Munich and Doctor of Osteopathic Medicine (D.O.) from the DAAO and EROP at the Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania.
neiu-This is a list of the 2017 presenters at NobelCon13. I have not seen a list for NobelCon14 for Jan.29-30 2018.
It does show how large and important these conferences are however. I would assume that Anavex will be presenting again in 2018.
Thank you for posting.
Mayo Clinic has begun a "Precision Medicine" study program some months ago to adjust dosages of meds on the individual patient's DNA/RNA etc.
as I understand it. As a patient at Mayo (Rochester) a number of times, I have been contacted and have given my concent to participate in their study.
They might be interested (imo) if the "Road Show" were scientific but this is an investors show.
Powerwalker, I pray that your visit there wasn't due to an extremely serious condition and that it resulted in a very positive outcome. With 3000 doctors and scientists working in a total teamwork concept, they do very thorough and wonderful work there.
Yes I stand corrected.(Not enough coffee yet when I posted.)
Dr. Gottlieb addresses congress 11/30 as I recall. Could it possibly be announced then or shortly after ?
Most excellent Investor. I had just read the article on Stock Gumshoe that Talon referred to on his post #131122 and so I forwarded your post to Dr. Gumshoe. I hope he will use your post as a guide to get fully familiar with Anavex careful progression.
Thanks Talon. Very interesting read.
Did anyone notice the "In Memoriam" at the top of the board today?
Did anyone notice the "In Memoriam" at the top of the board today?
Fireman- Remember Happy Hour from 4-5PM every Friday.
All posters can PM during that time frame plus other advantages of Level 2 as I remember such as advanced search etc.